利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3538人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660509, encodeId=a516166050971, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JASN：利妥昔单抗治疗严重膜性肾病的疗效研究, objectType=article, longId=217107, objectId=d7c121e107eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7c121e107eb, replyNumber=0, likeNumber=107, createdTime=2022-04-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7c121e107eb, moduleTitle=JASN：利妥昔单抗治疗严重膜性肾病的疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7c121e107eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660502, encodeId=be12166050284, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：利妥昔单抗vs.霉酚酸酯在寻常型天疱疮患者中的作用, objectType=article, longId=212854, objectId=cff5212854a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cff5212854a9, replyNumber=0, likeNumber=88, createdTime=2021-11-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cff5212854a9, moduleTitle=NEJM：利妥昔单抗vs.霉酚酸酯在寻常型天疱疮患者中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cff5212854a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660496, encodeId=8f8b1660496cf, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗, objectType=article, longId=204528, objectId=c65320452846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65320452846, replyNumber=0, likeNumber=75, createdTime=2021-09-29, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65320452846, moduleTitle=Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c65320452846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660498, encodeId=0f73166049893, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JAMA Netw Open：年轻患者采用利妥昔单抗治疗的不良反应发生情况, objectType=article, longId=206839, objectId=4e3320683942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e3320683942, replyNumber=0, likeNumber=70, createdTime=2021-11-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e3320683942, moduleTitle=JAMA Netw Open：年轻患者采用利妥昔单抗治疗的不良反应发生情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e3320683942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660494, encodeId=bc211660494f5, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, objectType=article, longId=201941, objectId=0be8201941c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be8201941c7, replyNumber=0, likeNumber=83, createdTime=2021-04-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be8201941c7, moduleTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be8201941c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660495, encodeId=960116604951a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=美罗华再迎新对手，第二款国产利妥昔单抗上市, objectType=article, longId=201962, objectId=c3af201962c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3af201962c0, replyNumber=0, likeNumber=56, createdTime=2021-01-04, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3af201962c0, moduleTitle=美罗华再迎新对手，第二款国产利妥昔单抗上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3af201962c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660497, encodeId=cac6166049e3c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, objectType=article, longId=206361, objectId=420e206361f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=420e206361f1, replyNumber=0, likeNumber=93, createdTime=2021-06-09, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=420e206361f1, moduleTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=420e206361f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660489, encodeId=6e391660489a0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠 , objectType=article, longId=193743, objectId=df92193e4370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df92193e4370, replyNumber=0, likeNumber=68, createdTime=2021-02-22, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df92193e4370, moduleTitle=抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df92193e4370)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660481, encodeId=5dac166048123, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, objectType=article, longId=187714, objectId=782818e714bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782818e714bf, replyNumber=0, likeNumber=85, createdTime=2020-05-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782818e714bf, moduleTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782818e714bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660480, encodeId=a2a9166048048, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛, objectType=article, longId=186322, objectId=1d521863220b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d521863220b, replyNumber=0, likeNumber=79, createdTime=2020-09-22, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d521863220b, moduleTitle=邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d521863220b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660490, encodeId=090a166049008, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：利妥昔单抗联合苯达莫司汀治疗冷凝集素病的长期预后, objectType=article, longId=194261, objectId=52b119426125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52b119426125, replyNumber=0, likeNumber=70, createdTime=2021-04-03, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52b119426125, moduleTitle=Blood：利妥昔单抗联合苯达莫司汀治疗冷凝集素病的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52b119426125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660484, encodeId=55b716604843c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Rheumatol：利妥昔单抗和环磷酰胺治疗抗合成酶综合征相关性ILD, objectType=article, longId=190543, objectId=6de319054325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6de319054325, replyNumber=0, likeNumber=109, createdTime=2021-02-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6de319054325, moduleTitle=J Rheumatol：利妥昔单抗和环磷酰胺治疗抗合成酶综合征相关性ILD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6de319054325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660479, encodeId=947616604e929, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, objectType=article, longId=185002, objectId=956e185002ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956e185002ad, replyNumber=0, likeNumber=75, createdTime=2020-07-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956e185002ad, moduleTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956e185002ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力, objectType=article, longId=193615, objectId=8cad19361569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cad19361569, replyNumber=0, likeNumber=76, createdTime=2020-11-11, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cad19361569, moduleTitle=JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cad19361569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660492, encodeId=72e01660492e1, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, objectType=article, longId=198980, objectId=03fb1989807e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fb1989807e, replyNumber=0, likeNumber=64, createdTime=2021-06-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fb1989807e, moduleTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fb1989807e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660487, encodeId=9eee166048e44, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=80, createdTime=2020-10-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660493, encodeId=daeb166049319, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤, objectType=article, longId=199989, objectId=134a199989af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134a199989af, replyNumber=0, likeNumber=75, createdTime=2021-07-04, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134a199989af, moduleTitle=Blood：维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134a199989af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660491, encodeId=808f1660491a1, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , objectType=article, longId=195309, objectId=a2e71953094c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e71953094c, replyNumber=0, likeNumber=65, createdTime=2021-05-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e71953094c, moduleTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e71953094c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660485, encodeId=1d2c166048526, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知, objectType=article, longId=190911, objectId=623b190911ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623b190911ab, replyNumber=0, likeNumber=70, createdTime=2020-09-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623b190911ab, moduleTitle=关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623b190911ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660482, encodeId=fb291660482d0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, objectType=article, longId=189157, objectId=3e3b18915ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e3b18915ec7, replyNumber=0, likeNumber=67, createdTime=2020-07-12, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e3b18915ec7, moduleTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e3b18915ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JASN：利妥昔单抗治疗严重膜性肾病的疗效研究

2022-04-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：利妥昔单抗vs.霉酚酸酯在寻常型天疱疮患者中的作用

2021-11-15

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗

2021-09-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JAMA Netw Open：年轻患者采用利妥昔单抗治疗的不良反应发生情况

2021-11-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤

2021-04-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

美罗华再迎新对手，第二款国产利妥昔单抗上市

2021-01-04

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？

2021-06-09

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠

2021-02-22

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤

2020-05-26

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛

2020-09-22

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：利妥昔单抗联合苯达莫司汀治疗冷凝集素病的长期预后

2021-04-03

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Rheumatol：利妥昔单抗和环磷酰胺治疗抗合成酶综合征相关性ILD

2021-02-15

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤

2020-07-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力

2020-11-11

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后

2021-06-26

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-10-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤

2021-07-04

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析

2021-05-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知

2020-09-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤

2020-07-12

科室
- - 订阅+
  - 更多科室
工具
服务